These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 30745392)

  • 1. Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
    Feng HP; Caro L; Fandozzi C; Chu X; Guo Z; Talaty J; Panebianco D; Dunnington K; Du L; Hanley WD; Fraser IP; Mitselos A; Denef JF; De Lepeleire I; de Hoon JN; Vandermeulen C; Marshall WL; Jumes P; Huang X; Martinho M; Valesky R; Butterton JR; Iwamoto M; Yeh WW
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
    Khatri A; Dutta S; Wang H; Podsadecki T; Trinh R; Awni W; Menon R
    Clin Infect Dis; 2016 Apr; 62(8):972-9. PubMed ID: 26740513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.
    Feng HP; Guo Z; Ross LL; Fraser I; Panebianco D; Jumes P; Fandozzi C; Caro L; Talaty J; Ma J; Mangin E; Huang X; Marshall WL; Butterton JR; Iwamoto M; Yeh WW
    J Antimicrob Chemother; 2019 Mar; 74(3):710-717. PubMed ID: 30541077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct-Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse-Transcriptase Inhibitor Tenofovir Disoproxil Fumarate.
    Feng HP; Guo Z; Caro L; Talaty JE; Mangin E; Panebianco D; Fandozzi C; Zhu Y; Marshall W; Huang X; Hanley WD; Jumes P; Valesky R; Martinho M; Butterton JR; Iwamoto M; Yeh WW
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):962-970. PubMed ID: 31173674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir.
    Ankrom W; Sanchez RI; Yee KL; Fan L; Mitra P; Wolford D; Triantafyllou I; Sterling LM; Stoch SA; Iwamoto M; Khalilieh S
    Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30782982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.
    Asante-Appiah E; Curry S; McMonagle P; Ingravallo P; Chase R; Nickle D; Qiu P; Howe A; Lahser FC
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28416549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No Pharmacokinetic Interaction Between the Hepatitis C Virus Inhibitors Elbasvir/Grazoprevir and Famotidine or Pantoprazole.
    Feng HP; Vaddady P; Guo Z; Liu F; Panebianco D; Levine V; Caro L; Butterton JR; Iwamoto M; Yeh WW
    Clin Transl Sci; 2017 Sep; 10(5):360-365. PubMed ID: 28625018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
    Sulkowski M; Hezode C; Gerstoft J; Vierling JM; Mallolas J; Pol S; Kugelmas M; Murillo A; Weis N; Nahass R; Shibolet O; Serfaty L; Bourliere M; DeJesus E; Zuckerman E; Dutko F; Shaughnessy M; Hwang P; Howe AY; Wahl J; Robertson M; Barr E; Haber B
    Lancet; 2015 Mar; 385(9973):1087-97. PubMed ID: 25467560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.
    Hulskotte EG; Feng HP; Xuan F; van Zutven MG; Treitel MA; Hughes EA; O'Mara E; Youngberg SP; Wagner JA; Butterton JR
    Clin Infect Dis; 2013 Mar; 56(5):718-26. PubMed ID: 23155151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Grazoprevir + elbasvir for the treatment of hepatitis C virus infection.
    Alric L; Bonnet D
    Expert Opin Pharmacother; 2016; 17(5):735-42. PubMed ID: 26933896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.
    Lahser FC; Bystol K; Curry S; McMonagle P; Xia E; Ingravallo P; Chase R; Liu R; Black T; Hazuda D; Howe AY; Asante-Appiah E
    Antimicrob Agents Chemother; 2016 May; 60(5):2954-64. PubMed ID: 26926625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical assessment of potential drug interactions of faldaprevir, a hepatitis C virus protease inhibitor, with darunavir/ritonavir, efavirenz, and tenofovir.
    Sabo JP; Kort J; Ballow C; Haschke M; Battegay M; Fuhr R; Girlich B; Schobelock M; Feifel U; Lang B; Li Y; Elgadi M
    Clin Infect Dis; 2014 Nov; 59(10):1420-8. PubMed ID: 25091302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
    Bifano M; Hwang C; Oosterhuis B; Hartstra J; Grasela D; Tiessen R; Velinova-Donga M; Kandoussi H; Sevinsky H; Bertz R
    Antivir Ther; 2013; 18(7):931-40. PubMed ID: 23963204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel.
    Marshall WL; Feng HP; Caro L; Talaty J; Guo Z; Huang X; Panebianco D; Ma J; Mangin E; O'Reilly TE; Butterton JR; Yeh WW
    Eur J Clin Pharmacol; 2017 May; 73(5):593-600. PubMed ID: 28233047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist Therapy.
    Feng HP; Guo Z; Caro L; Marshall WL; Liu F; Panebianco D; Vaddady P; Reitmann C; Jumes P; Wolford D; Fraser I; Valesky R; Martinho M; Butterton JR; Iwamoto M; Webster L; Yeh WW
    Clin Transl Sci; 2018 Nov; 11(6):553-561. PubMed ID: 30040872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C.
    Sulejmani N; Jafri SM; Gordon SC
    Expert Opin Drug Metab Toxicol; 2016; 12(3):353-61. PubMed ID: 26849059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I, Single- and Multiple-dose Study to Evaluate the Pharmacokinetics of Elbasvir and Grazoprevir in Healthy Chinese Participants.
    Cheung TT; Yan Chiu JW; Yuen MF; Ling Lam KS; Yung Cheung BM; Feng HP; Yeh WW; Wang J; Li W; Zhao XM; Wang Z; Mu S
    Clin Ther; 2018 May; 40(5):719-732.e1. PubMed ID: 29724498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Grazoprevir/elbasvir fixed-dose combination for hepatitis C.
    Gamal N; Andreone P
    Drugs Today (Barc); 2016 Jul; 52(7):377-85. PubMed ID: 27540596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy.
    Feng HP; Guo Z; Caro L; Marshall WL; Liu F; Panebianco D; Vaddady P; Barbour A; Reitmann C; Jumes P; Gilmartin J; Wolford D; Valesky R; Martinho M; Butterton JR; Iwamoto M; Fraser I; Webster L; Yeh WW
    Clin Transl Sci; 2018 Nov; 11(6):562-572. PubMed ID: 30040871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
    Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA
    Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.